Apellis Pharmaceuticals Inc (NASDAQ:APLS) CEO Cedric Francois sold 5,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $27.81, for a total transaction of $139,050.00.

Cedric Francois also recently made the following trade(s):

  • On Monday, September 16th, Cedric Francois sold 5,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $26.59, for a total transaction of $132,950.00.
  • On Thursday, August 15th, Cedric Francois sold 10,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $26.80, for a total transaction of $268,000.00.

NASDAQ APLS traded up $0.06 on Thursday, hitting $28.22. The stock had a trading volume of 719,005 shares, compared to its average volume of 471,102. Apellis Pharmaceuticals Inc has a one year low of $11.45 and a one year high of $33.18. The company has a quick ratio of 8.67, a current ratio of 8.67 and a debt-to-equity ratio of 0.08. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -12.06 and a beta of 0.68. The company’s 50-day moving average is $26.80 and its two-hundred day moving average is $24.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Wednesday, July 31st. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.18). On average, sell-side analysts anticipate that Apellis Pharmaceuticals Inc will post -3.91 earnings per share for the current year.

APLS has been the subject of several recent analyst reports. Oppenheimer initiated coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, July 9th. They issued an “outperform” rating and a $52.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $50.00 target price (down previously from $52.00) on shares of Apellis Pharmaceuticals in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 1st. ValuEngine cut shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Cowen set a $40.00 target price on shares of Apellis Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $45.14.

Several large investors have recently modified their holdings of APLS. BlackRock Inc. boosted its stake in Apellis Pharmaceuticals by 21.0% during the 2nd quarter. BlackRock Inc. now owns 4,502,117 shares of the company’s stock worth $114,085,000 after acquiring an additional 781,085 shares during the last quarter. Jennison Associates LLC increased its holdings in Apellis Pharmaceuticals by 57.2% during the second quarter. Jennison Associates LLC now owns 923,244 shares of the company’s stock worth $23,395,000 after buying an additional 335,863 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in Apellis Pharmaceuticals during the second quarter worth $4,361,000. DekaBank Deutsche Girozentrale acquired a new position in Apellis Pharmaceuticals during the second quarter worth $3,276,000. Finally, Point72 Asset Management L.P. increased its holdings in Apellis Pharmaceuticals by 20.2% during the second quarter. Point72 Asset Management L.P. now owns 401,104 shares of the company’s stock worth $10,164,000 after buying an additional 67,475 shares during the last quarter. 63.51% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Recommended Story: Why is cost of goods sold important?

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.